National Pension Service Has $91.92 Million Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

National Pension Service increased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 2.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 165,614 shares of the company’s stock after buying an additional 3,679 shares during the period. National Pension Service owned about 0.20% of IDEXX Laboratories worth $91,924,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Gotham Asset Management LLC lifted its position in shares of IDEXX Laboratories by 79.9% in the 3rd quarter. Gotham Asset Management LLC now owns 17,427 shares of the company’s stock worth $7,620,000 after purchasing an additional 7,741 shares during the period. NewEdge Wealth LLC lifted its position in shares of IDEXX Laboratories by 30.4% in the 3rd quarter. NewEdge Wealth LLC now owns 639 shares of the company’s stock worth $279,000 after purchasing an additional 149 shares during the period. Assenagon Asset Management S.A. increased its stake in shares of IDEXX Laboratories by 25.4% in the 4th quarter. Assenagon Asset Management S.A. now owns 43,593 shares of the company’s stock valued at $24,196,000 after acquiring an additional 8,831 shares in the last quarter. Carderock Capital Management Inc. increased its stake in shares of IDEXX Laboratories by 35.7% in the 4th quarter. Carderock Capital Management Inc. now owns 16,416 shares of the company’s stock valued at $9,112,000 after acquiring an additional 4,315 shares in the last quarter. Finally, Mitchell Capital Management Co. increased its stake in shares of IDEXX Laboratories by 1.3% in the 3rd quarter. Mitchell Capital Management Co. now owns 6,372 shares of the company’s stock valued at $2,786,000 after acquiring an additional 79 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories Stock Performance

NASDAQ IDXX traded up $12.50 during trading on Thursday, hitting $499.57. 194,633 shares of the company’s stock traded hands, compared to its average volume of 440,961. The stock has a market capitalization of $41.26 billion, a price-to-earnings ratio of 48.21, a PEG ratio of 3.78 and a beta of 1.27. IDEXX Laboratories, Inc. has a 12-month low of $372.50 and a 12-month high of $583.39. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.16 and a current ratio of 1.57. The business has a 50 day moving average of $519.60 and a 200-day moving average of $514.34.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Monday, February 5th. The company reported $2.32 EPS for the quarter, beating the consensus estimate of $2.12 by $0.20. IDEXX Laboratories had a net margin of 23.26% and a return on equity of 63.66%. The business had revenue of $901.60 million for the quarter, compared to the consensus estimate of $891.88 million. During the same period in the prior year, the firm earned $2.05 earnings per share. The company’s revenue was up 8.8% compared to the same quarter last year. As a group, equities research analysts anticipate that IDEXX Laboratories, Inc. will post 11.05 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Barclays lowered their price objective on shares of IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating for the company in a research note on Thursday, May 2nd. Piper Sandler downgraded shares of IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 price objective on the stock. in a report on Tuesday, January 30th. The Goldman Sachs Group lifted their price objective on shares of IDEXX Laboratories from $500.00 to $650.00 and gave the stock a “buy” rating in a report on Wednesday, January 17th. JPMorgan Chase & Co. lifted their price objective on shares of IDEXX Laboratories from $600.00 to $630.00 and gave the stock an “overweight” rating in a report on Tuesday, February 6th. Finally, William Blair reaffirmed an “outperform” rating on shares of IDEXX Laboratories in a report on Tuesday, April 9th. Four analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and a consensus price target of $580.88.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.